Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PES
2826
DELISTED
Pioneer Energy Services Corp.
PES
| $400K | ﹤0.01% |
195,198
+53,900
| +38% | +$155K |
|
2827
Lineage Cell Therapeutics
LCTX
$268M
| $396K | ﹤0.01% |
143,569
+22,614
| +19% | +$63.2K |
|
|
HFBC
2828
DELISTED
HopFed Bancorp Inc
HFBC
| $393K | ﹤0.01% |
27,400
-2,000
| -7% | -$29.1K |
|
|
MICR
2829
DELISTED
Micron Solutions, Inc.
MICR
| $391K | ﹤0.01% |
100,200
+3,000
| +3% | +$12.1K |
|
2830
Sensata Technologies
ST
$6.61B
| $389K | ﹤0.01% |
9,100
-303,100
| -97% | -$12.5M |
|
2831
Delek Logistics
DKL
$2.78B
| $388K | ﹤0.01% |
11,849
-22,071
| -65% | -$693K |
|
|
AFI
2832
DELISTED
Armstrong Flooring, Inc.
AFI
| $388K | ﹤0.01% |
21,600
+2,600
| +14% | +$48.7K |
|
|
TLGT
2833
DELISTED
Teligent, Inc
TLGT
| $387K | ﹤0.01% |
4,230
+1,696
| +67% | +$144K |
|
2834
Eagle Bancorp Montana
EBMT
$189M
| $386K | ﹤0.01% |
21,300
+5,300
| +33% | +$99.4K |
|
2835
Monolithic Power Systems
MPWR
$67B
| $386K | ﹤0.01% |
4,000
-300
| -7% | -$28.6K |
|
|
NBSE
2836
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $373K | ﹤0.01% |
1,458
+884
| +154% | +$237K |
|
|
CYAN
2837
DELISTED
Cyanotech Corp
CYAN
| $373K | ﹤0.01% |
105,000
+1,400
| +1% | +$5.17K |
|
|
SLCT
2838
DELISTED
Select Bancorp, Inc.
SLCT
| $373K | ﹤0.01% |
30,547
-153
| -0.5% | -$1.78K |
|
2839
Eldorado Gold
EGO
$10B
| $371K | ﹤0.01% |
+28,140
| New | +$459K |
|
|
TCS
2840
DELISTED
THE CONTAINER STORE GROUP, INC.
TCS
| $371K | ﹤0.01% |
4,173
-1,740
| -29% | -$125K |
|
|
NXTM
2841
DELISTED
NxStage Medical Inc.
NXTM
| $371K | ﹤0.01% |
14,783
-132,200
| -90% | -$3.27M |
|
|
VRML
2842
DELISTED
Vermillion, Inc.
VRML
| $370K | ﹤0.01% |
201,200
-48,700
| -19% | -$89K |
|
2843
Eledon Pharmaceuticals
ELDN
$286M
| $367K | ﹤0.01% |
3,488
+950
| +37% | +$96.8K |
|
2844
vTv Therapeutics
VTVT
$122M
| $367K | ﹤0.01% |
1,847
+252
| +16% | +$52.5K |
|
|
CMBT
2845
CMB.TECH NV
CMBT
$4.92B
| $367K | ﹤0.01% |
46,400
+10,300
| +29% | +$79.4K |
|
|
MMAC
2846
DELISTED
MMA Capital Holdings, Inc. Common Stock
MMAC
| $367K | ﹤0.01% |
16,062
-5,900
| -27% | -$137K |
|
|
BOJA
2847
DELISTED
Bojangles', Inc. Common Stock
BOJA
| $367K | ﹤0.01% |
22,600
-114,300
| -83% | -$2.11M |
|
|
KRA
2848
DELISTED
Kraton Corporation
KRA
| $365K | ﹤0.01% |
10,600
-320,700
| -97% | -$10.5M |
|
2849
Centrus Energy
LEU
$3.83B
| $364K | ﹤0.01% |
85,967
-16,933
| -16% | -$84.7K |
|
|
FAC
2850
DELISTED
First Acceptance Corp.
FAC
| $364K | ﹤0.01% |
319,600
+5,700
| +2% | +$6.78K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.